Predictive value of red blood cell distribution width and hematocrit for short-term outcomes and prognosis in colorectal cancer patients undergoing radical surgery

doi:10.3748/wjg.v30.i12.1714

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2261)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

HTML

1310

Figures (1-5)

248

Tables (1-5)

260

Sum=1877

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

231

Sum=304

Mar 28, 2024 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 28, 2024; 30(12): 1714-1726
Published online Mar 28, 2024. doi: 10.3748/wjg.v30.i12.1714

Table 1 Comparison between the higher red blood cell distribution width group and the lower red blood cell distribution width group

Characteristics	Higher RDW (n = 1573)	Lower RDW (n = 2685)	P value
RDW	17.3 ± 3.3	13.0 ± 0.6	< 0.01^a
Age, yr	64.1 ± 12.8	62.2 ± 11.7	< 0.01^a
Sex			< 0.01^a
Male	873 (55.5)	1640 (61.1)
Female	700 (44.5)	1045 (38.9)
BMI, kg/m²	22.3 ± 3.3	22.9 ± 3.1	< 0.01^a
Smoking	570 (36.2)	1047 (39.0)	0.074
Drinking	434 (27.6)	881 (32.8)	< 0.01^a
Hypertension	434 (27.6)	679 (25.3)	0.099
T2DM	222 (14.1)	319 (11.9)	0.035^a
CHD	90 (5.7)	91 (3.4)	< 0.01^a
Open surgery	281 (17.9)	282 (10.5)	< 0.01^a
Tumor location			< 0.01^a
Colon	940 (59.8)	1068 (39.8)
Rectum	633 (40.2)	1617 (60.2)
TNM stage			< 0.01^a
I	218 (13.9)	585 (21.8)
II	727 (46.2)	1020 (38.0)
III	538 (34.2)	976 (36.4)
IV	90 (5.7)	104 (3.8)
Tumor size			< 0.01^a
< 5 cm	739 (47.0)	1716 (63.9)
≥ 5 cm	834 (53.0)	969 (36.1)
Operation time (min)	230.3 ± 81.9	225.8 ± 84.1	0.087
Blood loss (mL)	116.4 ± 171.8	93.3 ± 131.0	< 0.01^a
Hospital stay (d)	11.5 ± 7.7	11.2 ± 9.2	0.283
Overall complications	400 (25.4)	538 (20.0)	< 0.01^a
Major complications	42 (2.7)	60 (2.2)	0.370

^aP value < 0.05.

Variables are expressed as the mean ± SD, n (%). RDW: Red blood cell distribution width; T2DM: Type 2 diabetes mellitus; BMI: Body mass index; CHD: Coronary heart disease; TNM: Tumor node metastasis.

Table 2 Comparison between the higher hematocrit group and the lower hematocrit group

Characteristics	Higher hematocrit (n = 2166)	Lower hematocrit (n = 2092)	P value
Hematocrit	42.1 ± 3.0	32.2 ± 4.4	< 0.01^a
Age, yr	61.2 ± 11.3	64.6 ± 12.7	< 0.01^a
Sex			< 0.01^a
Male	1580 (72.9)	933 (44.6)
Female	586 (27.1)	1159 (55.4)
BMI, kg/m²	23.2 ± 3.1	22.2 ± 3.2	< 0.01^a
Smoking	1023 (47.2)	594 (28.4)	< 0.01^a
Drinking	839 (38.7)	476 (22.8)	< 0.01^a
Hypertension	540 (24.9)	573 (27.4)	0.068
T2DM	220 (10.2)	321 (15.3)	< 0.01^a
CHD	68 (3.1)	113 (5.4)	< 0.01^a
Open surgery	222 (10.2)	341 (16.3)	< 0.01^a
Tumor location			< 0.01^a
Colon	782 (36.1)	1226 (58.6)
Rectum	1384 (63.9)	866 (41.4)
TNM stage			< 0.01^a
I	485 (22.4)	318 (15.2)
II	847 (39.1)	900 (43.0)
III	750 (34.6)	764 (36.5)
IV	84 (3.9)	110 (5.3)
Tumor size			< 0.01^a
< 5 cm	1415 (65.3)	1040 (49.7)
≥ 5 cm	751 (34.7)	1052 (50.3)
Operation time (min)	228.1 ± 85.4	226.8 ± 81.1	0.593
Blood loss (mL)	96.3 ± 138.0	107.6 ± 157.1	0.012^a
Hospital stay (d)	11.0 ± 7.5	11.6 ± 9.8	0.016^a
Overall complications	419 (19.3)	519 (24.8)	< 0.01^a
Major complications	53 (2.4)	49 (2.3)	0.823

^aP value < 0.05.

Variables are expressed as the mean ± SD, n (%). T2DM: Type 2 diabetes mellitus; BMI: Body mass index; CHD: Coronary heart disease; TNM: Tumor node metastasis.

Table 3 Univariate and multivariate logistic regression analysis of the overall complications

Risk factors	Univariate analysis		Multivariate analysis
Risk factors	OR (95%CI)	P value	OR (95%CI)	P value
Age, yr	1.024 (1.018-1.030)	< 0.01^a	1.018 (1.011-1.025)	< 0.01^a
Sex (male/female)	0.901 (0.777-1.045)	0.166
BMI, kg/m²	0.973 (0.951-0.995)	0.018^a	0.983 (0.959-1.007)	0.160
Hypertension (yes/no)	1.358 (1.158-1.592)	< 0.01^a	1.128 (0.944-1.347)	0.186
T2DM (yes/no)	1.553 (1.270-1.900)	< 0.01^a	1.297 (1.045-1.610)	0.018^a
Tumor location (colon/rectum)	0.966 (0.835-1.117)	0.638
Tumor stage (IV/III/II/I)	1.053 (0.963-1.151)	0.257
Smoking (yes/no)	1.173 (1.012-1.360)	0.034^a	1.255 (1.075-1.464)	0.004^a
Drinking (yes/no)	0.989 (0.845-1.157)	0.893
CHD (yes/no)	1.807 (1.314-2.484)	< 0.01^a	1.365 (0.977-1.908)	0.069
Tumor size (≥ 5/< 5), cm	1.214 (1.049-1.404)	0.009^a	1.059 (0.910-1.234)	0.459
Surgical methods (open/laparoscopic)	2.250 (1.860-2.721)	< 0.01^a	2.056 (1.691-2.500)	< 0.01^a
RDW (lower/higher)	0.735 (0.634-0.852)	< 0.01^a	0.887 (0.749-1.050)	0.163
Hematocrit (lower/higher)	1.376 (1.189-1.591)	< 0.01^a	1.165 (0.981-1.383)	0.082

^aP value < 0.05.

RDW: Red blood cell distribution width; OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; T2DM: Type 2 diabetes mellitus; CHD: Coronary heart disease.

Table 4 Univariate and multivariate analysis of overall survival

Risk factors	Univariate analysis		Multivariate analysis
Risk factors	HR (95%CI)	P value	HR (95%CI)	P value
Age (yr)	1.044 (1.036-1.051)	< 0.01^a	1.038 (1.030-1.046)	< 0.01^a
Sex (female/male)	0.861 (0.730-1.015)	0.074
BMI (kg/m²)	0.959 (0.935-0.984)	0.001^a	0.997 (0.972-1.023)	0.840
T2DM (yes/no)	1.303 (1.038-1.636)	0.022^a	0.941 (0.745-1.189)	0.610
Tumor site (colon/ rectum)	1.422 (1.091-1.853)	0.009^a	0.984 (0.831-1.165)	0.851
Tumor stage (IV/III/II/I)	2.202 (1.979-2.452)	< 0.01^a	2.167 (1.943-2.416)	< 0.01^a
Smoking (yes/no)	1.081 (0.918-1.273)	0.351
Drinking (yes/no)	1.070 (0.901-1.271)	0.438
Hypertension (yes/no)	1.055 (0.879-1.266)	0.564
CHD (yes/no)	1.355 (0.939-1.957)	0.105
Tumor size (≥ 5 cm/< 5 cm)	1.532 (1.305-1.799)	< 0.01^a	1.235 (1.044-1.459)	0.014^a
RDW (lower/higher)	0.664 (0.565-0.780)	< 0.01^a	0.925 (0.774-1.107)	0.396
Hematocrit (lower/higher)	1.693 (1.437-1.995)	< 0.01^a	1.256 (1.041-1.515)	0.017^a
Overall complications (yes/no)	1.903 (1.611-2.248)	< 0.01^a	1.608 (1.357-1.904)	< 0.01^a

^aP value < 0.05.

RDW: Red blood cell distribution width; HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; T2DM: Type 2 diabetes mellitus.

Table 5 Univariate and multivariate analysis of disease-free survival

Risk factors	Univariate analysis		Multivariate analysis
Risk factors	HR (95%CI)	P value	HR (95%CI)	P value
Age (yr)	1.031 (1.025-1.038)	< 0.01^a	1.027 (1.020-1.033)	< 0.01^a
Sex (female/male)	0.861 (0.730-1.015)	0.058
BMI (kg/m²)	0.975 (0.953-0.997)	0.029^a	1.003 (0.981-1.026)	0.784
T2DM (yes/no)	1.127 (0.911-1.396)	0.271
Tumor site (colon/ rectum)	1.126 (0.975-1.300)	0.107
Tumor stage (IV/III/II/I)	2.120 (1.926-2.334)	< 0.01^a	2.093 (1.900-2.307)	< 0.01^a
Smoking (yes/no)	1.093 (0.944-1.267)	0.234
Drinking (yes/no)	1.104 (0.946-1.288)	0.208
Hypertension (yes/no)	1.036 (0.879-1.220)	0.676
CHD (yes/no)	1.281 (0.917-1.791)	0.147
Tumor size (≥ 5 cm/< 5 cm)	1.363 (1.180-1.574)	< 0.01^a	1.115 (0.962-1.294)	0.149
RDW (lower/higher)	0.713 (0.616-0.824)	< 0.01^a	0.920 (0.783-1.080)	0.308
Hematocrit (lower/higher)	1.509 (1.304-1.747)	< 0.01^a	1.194 (1.013-1.408)	0.035^a
Overall complications (yes/no)	1.705 (1.463-1.987)	< 0.01^a	1.510 (1.293-1.763)	< 0.01^a

^aP value < 0.05.

RDW: Red blood cell distribution width; HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; T2DM: Type 2 diabetes mellitus; CHD: Coronary heart disease.

Citation: Peng D, Li ZW, Liu F, Liu XR, Wang CY. Predictive value of red blood cell distribution width and hematocrit for short-term outcomes and prognosis in colorectal cancer patients undergoing radical surgery. World J Gastroenterol 2024; 30(12): 1714-1726
URL: https://www.wjgnet.com/1007-9327/full/v30/i12/1714.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i12.1714